Skip to main content
SpringerLink
Log in

Inhibitory effects of medroxyprogesterone acetate (MPA) and the pure antiestrogen EM-219 on estrone (E1)-stimulated growth of dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat

  • Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

Estrogens are well known to play a predominant role in promoting the growth of DMBA-induced mammary tumors in the rat. Estrone (E1), a steroid having weak estrogenic activity, is one of most important estrogens in post-menopausal women, where it is converted into the potent estrogen estradiol (E2) by 17β-hydroxysteroid dehydrogenase (17β-HSD) in many peripheral tissues, including the mammary gland. In this report, we have studied the effect of a new antiestrogen (EM-219) (N-butyl, N-methyl-11-(3′, 17′β-dihydroxy-17′α-ethinylestra-1′3′5′(10′), 14′-tetraen-7′α-yl) undecanamide) on E1-stimulated growth of DMBA-induced mammary tumors and compared its effect with that of medroxyprogesterone acetate (MPA) alone or in combination. After 18 days, ovariectomy (OVX) reduced total tumor area to 29.6 ± 7.1% of the original size, while E1 (1.0 µg, twice daily) caused a 139 ± 21% increase in tumor size in OVX animals. MPA (1.5 mg, twice daily) partially reversed the stimulatory effect of E1 to 66.0 ± 9.0%, while the antiestrogen EM-219 (40 µg, twice daily) decreased tumor size to 70.0 ± 10%. Combination of these two compounds led to a further inhibition of tumor size to 30.7 ± 7.4% of the value found in OVX animals treated with E1. Tumor E2 levels decreased from 1688 ± 155 pmoles/kg tissue in OVX animals receiving E1 to 709 ± 92, 1347 ± 98, and 184 ± 11 pmoles/kg tissue in MPA-, EM-219-, and MPA + EM-219-treated OVX-E1 animals, respectively. Treatment of OVX animals with E1 increased by 69% the reductive activity of 17β-hydroxysteroid dehydrogenase (17β-HSD) while MPA abolished completely this effect of E1. In the oxidative direction, treatment with E1, E1 + MPA, or E1 + EM-219 had minimal or no significant effect on the activity of 17β-HSD (vs OVX), while the combined treatment with MPA + EM-219 induced a 2-fold increase in 17β-HSD activity, thus leading to an increased conversion of E2 into E1. The present data show that combination of the pure antiestrogen EM-219 with MPA exerts a greater reduction in DMBA-induced mammary tumor growth and intratumoral E2 levels stimulated by E1 than either compound used alone. This interactive effect of the antiestrogen and MPA could at least partially be related to the increased inactivation of E2 into E1. The present data suggest that such a combination could be a useful approach for the treatment of breast cancer, especially in post-menopausal women.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. McGuire WL, Carbone PP, Sears ME, Escher GC: Estrogen receptors in human breast cancer: an overview. In: McGuire WL, Carbone PP, Vollmer EP (eds) Estrogen Receptors in Human Breast Cancer. Raven Press, New York, 1975, pp. 1–7

    Google Scholar 

  2. Henderson BE, Ross R, Bernstein L: Estrogens as a cause of human cancer: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 48: 246–253, 1988

    Google Scholar 

  3. Asselin J, Labrie F, Kelly PA, Philibert D, Raynaud JP: Specific progesterone receptors in DMBA-induced mammary tumors. Steroids 27: 395–404, 1976

    Google Scholar 

  4. Poulin R, Labrie F: Stimulation of cell proliferation and estrogenic response by adrenal C19-△5 steroids in the ZR-75-1 human breast cancer cell line. Cancer Res 46: 4933–4936, 1986

    Google Scholar 

  5. Wells SA Jr, Santen RJ: Ablative procedures in patients with metastatic breast cancer. Cancer 53: 762–765, 1984

    Google Scholar 

  6. Miller WR: Fundamental research leading to improved endocrine therapy for breast cancer. J Steroid Biochem 27: 477–485, 1987

    Google Scholar 

  7. McNab MW, Tallarida RJ, Joseph R: An evaluation of tamoxifen as a partial agonist by classical receptor thory, an explanation of the dual action of tamoxifen. Eur J Pharmacol 103: 321–326, 1984

    Google Scholar 

  8. Furr BJ, Jordan VC: The pharmacology and clinical uses of tamoxifen. Pharmac Ther 25: 125–205, 1984

    Google Scholar 

  9. Horwitz KB, McGuire WL: Antiestrogen: mechanisms of action and effects in breast cancer. In: McGuire WL (ed) Breast Cancer: Advances in Research and Treatment, Plenum Press, New York, 1978, pp. 155–204

    Google Scholar 

  10. Wakeling AE, Slater SR: Biochemical and biological aspects of antiestrogen action. In: Lewis GP, Gringburg GP (eds) Mechanisms of Hormone Action, McMillan Press, London, 1981, pp. 159–171

    Google Scholar 

  11. Poulin R, Mérand Y, Poirier D, Lévesque C, Dufour J, Labrie F: Antiestrogenic properties of keoxifene, trans-4-hydroxytamoxifen, and ICI 164384, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells. Breast Cancer Res Treatm 14: 65–76, 1989

    Google Scholar 

  12. Lévesque C, Mérand Y, Dufour JM, Labrie C, Labrie F: Synthesis and biological activity of new halo-steroidal antiestrogens. J Med Chem 34: 1624–1630, 1991

    Google Scholar 

  13. Labrie C, Martel C, Lévesque C, Mérand Y, Labrie F: Novel compounds inhibit both estrogen formation and action. Cancer Res 52: 610–615, 1992

    Google Scholar 

  14. Simard J, Dauvois S, Haagensen DE, Lévesque C, Mérand Y, Labrie F: Regulation of progesterone-binding breast cyst protein GCDFP-24 secretion by estrogens and androgens in human breast cancer cells: a new marker of steroid action in breast cancer. Endocrinology 126: 3223–3231, 1989

    Google Scholar 

  15. De Launoit Y, Dauvois S, Dufour M, Simard J, Labrie F: Inhibition of cell cycle kinetics and proliferation by the androgen 5α-dihydrotestosterone and antiestrogen N,n-butyl-n-methyl-11-[16′α-chloro-3′,17β-dihydroxy-estra-1′,3′,5′-(10′)-triene-7′α-yl] undecanamide in human breast cancer ZR-75-1 cells. Cancer Res 51: 2797–2802, 1991

    Google Scholar 

  16. Huggins C, Briziarelli G, Sutton H Jr: Rapid induction of mammary carcinoma in the rat and the influence of hormones on the tumors. J Expl Med 109: 25–41, 1959

    Google Scholar 

  17. Dauvois S, Li S, Martel C, Labrie F: Inhibitory effect of androgens on DMBA-induced mammary carcinoma in the rat. Breast Cancer Res Treatm 14: 299–306, 1989

    Google Scholar 

  18. Siiteri PK, MacDonald PC: The role of extraglandular estrogen in human endocrinology. In: Freiger SR, Astwood EB, Greep RO (eds) Handbook of Physiology Section 7, The American Physiology Society, New York, 1973, pp. 615–629

    Google Scholar 

  19. Labrie F, Simard J, Luu-The V, Trudel C, Martel C, Labrie C, Zhao HF, Rhéaume E, Couet J, Breton N: Expression of 3β-hydroxysteroid dehydrogenase/△5-△4 isomerase (3β-HSD) and 17β-hydroxysteroid dehydrogenase (17β-HSD) in adipose tissue. Int J Obesity 15: 91–99, 1991

    Google Scholar 

  20. Haller DG, Glick JH: Progestational agents in advanced breast cancer: an overview. Semin Oncol 13: 2–8, 1986 (suppl)

    Google Scholar 

  21. Van Veelen H, Willemse PHB, Sleijfer DT, Van der Ploeg E, Sluiter WJ, Doorenbos H: Mechanism of adrenal suppression of high-dose medroxyprogesterone acetate in breast cancer patients. Cancer Chemother Pharmacol 15: 167–170, 1985

    Google Scholar 

  22. Dauvois S, Spinola PG, Labrie F: Additive inhibitory effects of bromocriptine (CB-154) and medroxyprogesterone acetate (MPA) on dimethylbenz(a)anthracene (DMBA)-induced mammary tumors in the rat. Eur J Cancer Clin Oncol 25: 891–897, 1989

    Google Scholar 

  23. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 238–254, 1977

    Google Scholar 

  24. Bélanger A, Labrie F, Angeli A: Unconjugated and glucuronide steroid levels in human breast cyst fluid. In: Angeli A, Bradlow HL, Chasalow FI, Gogliotti L (eds) Biochemistry of Breast Cyst Fluid. Correlation with Breast Cancer Risk. Ann New York Acad Sci 586: 93–100, 1990

    Google Scholar 

  25. Kramer CY: Extension of multiple range tests to group means with unequal numbers of replications. Biometrics 12: 307–310, 1956

    Google Scholar 

  26. Poulin R, Baker D, Labrie F: Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line. Breast Cancer Res Treatm 12: 213–225, 1988

    Google Scholar 

  27. Poulin R, Baker D, Poirier D, Labrie F: Androgen and glucocorticoid receptor-mediated inhibition of cell proliferation by medroxyprogesterone acetate in ZR-75-1 human breast cancer cells. Breast Cancer Res Treatm 13: 161–172, 1989

    Google Scholar 

  28. Dauvois S, Geng CS, Lévesque C, Mérand Y, Labrie F: Additive inhibitory effects of an androgen and the antiestrogen EM-170 on estradiol-stimulated growth of human ZR-75-1 breast cancer tumors in athymic mice. Cancer Res 51: 3131–3135, 1991

    Google Scholar 

  29. Simard J, Hatton AC, Labrie C, Dauvois S, Zhao HF, Haagensen DE, Labrie F: Inhibitory effect of estrogens on GCDFP-15 mRNA levels and secretion in ZR-75-1 human breast cancer cells. Mol Endocrinol 31: 694–702, 1989

    Google Scholar 

  30. Poulin R, Simard J, Labrie C, Petitclerc L, Dumont M, Lagacé L, Labrie F: Down-regulation of estrogen receptors by androgens in the ZR-75-1 human breast cancer cell line. Endocrinology 125: 392–399, 1989

    Google Scholar 

  31. Labrie F, Simard J, De Launoit Y, Poulin R, Thériault C, Dumont M, Dauvois S, Martel C, Li S: Androgens and breast cancer. Cancer Detection and Prevention 16: 31–38, 1992

    Google Scholar 

  32. Tormey DC, Lippman ME, Cassidy JG: Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer. Ann Intern Med 98: 139–143, 1983

    Google Scholar 

  33. Ingle JN, Twito DI, Sharid DJ, Cullinan SA, Krook JE, Mailliard JA, Tschetter LK, Long HJ, Gerstner JG, Windschitl HEet al.: Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in post-menopausal women with metastatic breast cancer. An updated analysis. Cancer 76: 886–891, 1991

    Google Scholar 

  34. Labrie F: Intracrinology. At the cutting edge. Mol Cell Endocrinol 78: C113-C118, 1991

    Google Scholar 

  35. Labrie F, Dupont A, Bélanger A: Complete androgen blockade for the treatment of prostate cancer: In: de Vita S, Hellman S, Rosenberg SA (eds) Important Advances in Oncology, JB Lippincott, Philadelphia: pp. 193–200, 1985

    Google Scholar 

  36. Adams JB: Control of secretion and the function of C19-delta-5-steroid of the human adrenal gland. Mol Cell Endocrinol 41: 1–17, 1985

    Google Scholar 

  37. Horton R, Tait JK: Androstenedione production and interconversion rates measured in peripheral blood and studies on the possible site of its conversion to testosterone. J Clin Invest 45: 303–313, 1966

    Google Scholar 

  38. Baird BT, Horton R, Longcope C, Tait JF: Steroid dynamics under steady-state conditions. Rec Progr Horm Res 26: 611–664, 1969

    Google Scholar 

  39. Vermeulen A: The hormonal activity of the postmenopausal ovary. J Clin Endocrinol Metab 42: 247–253, 1976

    Google Scholar 

  40. Dauvois S, Labrie F: Androstenedione and androstene-3β,17β-diol stimulate DMBA-induced rat mammary tumors- role of aromatase. Breast Cancer Res Treatm 13: 61–69, 1989

    Google Scholar 

  41. Labrie F, Luu-The V, Labrie C, Bérubé D, Couet J, Zhao HF, Gagné R, Simard J: Characterization of two mRNA species encoding human estradiol 17β-dehydrogenase and assignment of the gene to chromosome 17. J Steroid Biochem 34: 189–197, 1989

    Google Scholar 

  42. Luu-The V, Lachance Y, Simard J, Labrie C, Zhao HF, Couet J, Leblanc G, Labrie F: Structure of two in tandem human 17β-hydroxysteroid dehydrogenase genes. Mol Endocrinol 4: 268–275, 1990

    Google Scholar 

  43. Prudhomme JF, Malet C, Gompel A, Lalardrie JP, Ochoa C, Boue A, Mauvais-Jarvis P, Kuttenn F: 17β-hydroxysteroid dehydrogenase activity in human breast epithelial cell and fibroblast culture. Endocrinology 114: 1483–1489, 1984

    Google Scholar 

  44. Tait GH, Newton CJ, Reed MJ, James VH: Multiple forms of 17β-hydroxysteroid oxidoreductase in human breast tissue. J Mol Endocrinol 2: 71–80, 1989

    Google Scholar 

  45. Thériault C, Labrie F: Multiple steroid metabolic pathways in ZR-75-1 human breast cancer cells. J Steroid Biochem Molec Biol 38: 155–164, 1991

    Google Scholar 

  46. Couture P, Thériault C, Simard J, Labrie F: Androgen receptor-mediated stimulation of 17β-hydroxysteroid dehydrogenase activity by dihydrotestosterone and medroxyprogesterone acetate in ZR-75-1 human breast cancer cells. Endocrinology 132: 179–185, 1993

    Google Scholar 

  47. Li S, Martel C, Dauvois S, Bélanger A, Labrie F: Effect of estrone on the growth of 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat: a model of post-menopausal breast cancer. Endocrinology 134: 1352–1357, 1993

    Google Scholar 

  48. Pasqualini JR, Gelly C, Nguyen B-L, Vella C: Importance of estrogen sulfates in breast cancer. J Steroid Biochem 34: 155–163, 1989

    Google Scholar 

  49. Adams EF, Coldham NG, James VHT: Steroidal regulation of oestradiol-17β-dehydrogenase activity of the human breast cancer cell line MCF-7. J Endocrinol 118: 149–154, 1988

    Google Scholar 

  50. McNeil M, Reed MJ, Beranek PA, Bonney RC, Chilchich MW, Robinson DJ, James VHT: A comparison of thein vivo uptake and metabolism of3H-oestrone and3H-estradiol by normal breast and breast tumor tissue in postmenopausal women. Int J Cancer 38: 193–196, 1986

    Google Scholar 

  51. Beranek PA, Folkerd EJ, Newton CJ, Reed MJ, Gilchik MW, James VHT: The relationship between 17β-hydroxysteroid dehydrogenase activity and breast tumor site and size. Int J Cancer 36: 685–687, 1985

    Google Scholar 

  52. Singh A, Reed MJ, Gilchik MW, James VHT: The effect of breast tumor and normal breast tissue cytosols on oestradiol 17β-hydroxysteroid dehydrogenase activity. Cancer Lett 44: 45–48, 1989

    Google Scholar 

  53. Poutanen M, Isomaa V, Kainulainen K, Vihko R: Progestin induction of 17β-hydroxysteroid dehydrogenase enzyme protein in the T-47D human breast cancer cell line. Int J Cancer 46: 897–901, 1990

    Google Scholar 

  54. Poulin R, Baker D, Poirier D, Labrie F: Androgen and glucocorticoid receptor mediated inhibition of cell proliferation by medroxyprogesterone acetate in ZR-75-1 human breast cancer cells. Breast Cancer Res Treatm 13: 161–172, 1989

    Google Scholar 

  55. Blossey HC, Wander HE, Koebberling J, Nagel GA: Pharmacokinetic and pharmacodynamics for the treatment of metastatic breast cancer with high-dose medroxyprogesterone acetate. Cancer 54: 1208–1215, 1984

    Google Scholar 

  56. Adams EF, Newton CJ, Tait GH, Braunsberg H, Reed MJ, James VHT: Paracrine influence of human breast stromal fibroblasts on breast epithelial cells: secretion of a polypeptide which stimulates reductive 17β-oestradiol dehydrogenase activity. Int J Cancer 42: 119–122, 1988

    Google Scholar 

  57. Pelletier G, Leclerc R, Labrie F: Identification of gonadotrophs in human pituitary by an immunoperoxidase technique. Mol Cell Endocrinol 6: 123–128, 1976

    Google Scholar 

  58. Ferland L, Drouin J, Labrie F: Role of sex steroids on LH and FSH secretion in the rat. In: Labrie F, Meites J, Pelletier G (eds) Hypothalamus and Endocrine Functions, Plenum Press, New York, 1976, pp. 191–209

    Google Scholar 

  59. Cusan L, Auclair C, Bélanger A, Ferland L, Kelly PA, Séguin C, Labrie F: Inhibitory effects of long-term treatment with an LHRH agonist on the pituitary-gonadal axis in male and female rats. Endocrinology 104: 1369–1376, 1979

    Google Scholar 

  60. Labrie C, Cusan L, Plante M, Lapointe S, Labrie F: Analysis of the androgenic activity of synthetic ‘progestins’ currently used for the treatment of prostate cancer. J Steroid Biochem 28: 379–384, 1987

    Google Scholar 

  61. Luthy IA, Bégin DJ, Labrie F: Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture. J Steroid Biochem 31: 845–852, 1988

    Google Scholar 

  62. Plante M, Lapointe S, Labrie F: Stimulatory effect of synthetic progestins currently used for the treatment of prostate cancer on growth of the androgen-sensitive Shionogi tumor in mice. J Steroid Biochem 31: 61–64, 1988

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. MRC Group in Molecular Endocrinology, CHUL Research Center, 2705 Laurier Boulevard, Quebec, G1V 4G2, Québec, Canada

    Shengmin Li, Charles Lévesque, Chang-Shan Geng, Xu Yan & Fernand Labrie

Authors
  1. Shengmin Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charles Lévesque
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chang-Shan Geng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xu Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fernand Labrie
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Li, S., Lévesque, C., Geng, CS. et al. Inhibitory effects of medroxyprogesterone acetate (MPA) and the pure antiestrogen EM-219 on estrone (E1)-stimulated growth of dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat. Breast Cancer Res Tr 34, 147–159 (1995). https://doi.org/10.1007/BF00665787

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00665787

Key words

Search

Navigation